Immix Biopharma, Inc.
IMMX
$4.15
$0.184.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.91% | 26.31% | 37.48% | 53.69% | 50.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.28% | 17.78% | 13.31% | 40.48% | 58.40% |
| Operating Income | -4.28% | -17.78% | -13.31% | -40.48% | -58.40% |
| Income Before Tax | -6.92% | -20.23% | -13.42% | -39.10% | -54.77% |
| Income Tax Expenses | -2.87% | 19.41% | 40.00% | 55.30% | 62.29% |
| Earnings from Continuing Operations | -6.90% | -20.22% | -13.46% | -39.13% | -54.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -100.00% | -94.22% | -49.85% | 45.66% |
| Net Income | -7.64% | -21.58% | -14.78% | -40.11% | -54.85% |
| EBIT | -4.28% | -17.78% | -13.31% | -40.48% | -58.40% |
| EBITDA | -3.42% | -17.24% | -13.00% | -40.32% | -58.33% |
| EPS Basic | 9.31% | 7.31% | 23.21% | 11.08% | 7.18% |
| Normalized Basic EPS | 8.87% | 6.64% | 22.71% | 10.79% | 7.26% |
| EPS Diluted | 9.31% | 7.31% | 23.21% | 11.08% | 7.18% |
| Normalized Diluted EPS | 8.87% | 6.64% | 22.71% | 10.79% | 7.26% |
| Average Basic Shares Outstanding | 17.16% | 28.18% | 49.01% | 60.49% | 68.38% |
| Average Diluted Shares Outstanding | 17.16% | 28.18% | 49.01% | 60.49% | 68.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |